Abstract：
Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. We aim to obtain a better understanding of the clinical status and disease burden of patients with asthma in China. A retrospective study was carried out based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (available data from 38 hospitals). The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to Global Initiative for Asthma 2020 (GINA 2020). The results revealed that the majority (75.0%) of patients suffered from mild asthma. Patients treated with inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) at emergency department visits had lower frequencies of exacerbations compared with non-ICS/LABA-treated patients. The incidence rates for 1, 2, 3, and 4 exacerbation of the patients treated with ICS/LABA are lower than those treated without ICS/LABA (14.49 vs. 15.01%, 11.94% vs. 19.12%, 6.51% vs.12.92% and 4.10% vs. 9.35%). The difference got a statistical significance Chronic obstructive pulmonary disease (COPD) and gastroesophageal reflux disease (GERD), two comorbidities related to asthma, were risk factors for asthma exacerbation. Finally, patients who suffered from exacerbations produced a heavier economic burden compared to the patients who never suffered exacerbations (mean costs are ￥3,339.67 vs. ￥968.45 separately). These results provide a reference for clinicians and patients to obtain a better treatment and therapy strategy management for people living with asthma.
摘要：
哮喘是一种常见的慢性气道炎症，对经济产生医疗负担。我们旨在更好地了解中国哮喘患者的临床状况和疾病负担。根据2011年至2019年济南健康医疗大数据平台的计算机病历（来自38家医院的可用数据）进行了回顾性研究。回顾性评估每位患者的哮喘严重程度，并将其分类为轻度，中度,根据2020年全球哮喘倡议（GINA2020），或严重。结果显示，大多数（75.0％）的患者患有轻度哮喘。与未接受ICS/LABA治疗的患者相比，在急诊科就诊时接受吸入性皮质类固醇（ICS）/长效β受体激动剂（LABA）治疗的患者的恶化频率较低。使用ICS/LABA治疗的患者的1、2、3和4个恶化的发生率低于不使用ICS/LABA治疗的患者（14.49vs.15.01%,11.94%与19.12%,6.51%vs.12.92%和4.10%vs.9.35%）。慢性阻塞性肺疾病(COPD)和胃食管反流病(GERD),两种与哮喘有关的合并症,是哮喘加重的危险因素。最后,与从未遭受过恶化的患者相比，遭受恶化的患者产生了更重的经济负担(平均费用为USD3,339.67vs.¥968.45元另存)。这些结果为临床医师和患者获得更好的哮喘患者治疗和治疗策略管理提供了参考。
